LifeMD launches Novo Nordisk Wegovy subscription program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- Lula, Brazil's iconic working class president, wins historic fourth term in dramatic comeback
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
- Accenture shares fall on insider sales and analyst downgrade
- Wall Street closes lower to end rocky week
- Credo Technology shares fall on competition concerns
LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program
March 31, 2026 8:45 AM EDTNEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the launch of Novo Nordisk's new Wegovy® (semaglutide) subscription program the first and only GLP-1 subscription offering of its kind now available through LifeMD. The program meaningfully expands patient access to branded GLP-1 therapy and supports treatment adherence with significant cost savings.
The subscription model marks a significant... More



